FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
-5.26%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$437M
AUM Growth
+$437M
(+3.3%)
Cap. Flow
+$75.9M
Cap. Flow
% of AUM
17.37%
Top 10 Holdings %
Top 10 Hldgs %
66.91%
Holding
28
New
6
Increased
6
Reduced
6
Closed
1
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$35.4M |
| 2 |
Neurocrine Biosciences
NBIX
|
$27.6M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$18M |
| 4 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$13.4M |
| 5 |
DBVT
DBV Technologies
DBVT
|
$12.3M |
Top Sells
| 1 |
argenx
ARGX
|
$19.2M |
| 2 |
Protagonist Therapeutics
PTGX
|
$13M |
| 3 |
Insmed
INSM
|
$12.3M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$7.31M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$5.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Astria Therapeutics
ATXS
$349M
| $2.74M | 0.63% |
911,736
| – | – |
|
|
ALLK
27
DELISTED
Allakos
ALLK
| $461K | 0.11% |
147,189
| – | – |
|
|
28
Protagonist Therapeutics
PTGX
$3.67B
| – | – |
-549,988
| Closed | -$13M |
|